表紙
市場調查報告書

液態切片的全球市場

The World Liquid Biopsy Market

出版商 Kalorama Information 商品編碼 876845
出版日期 內容資訊 英文 210 Pages
商品交期: 最快1-2個工作天內
價格
液態切片的全球市場 The World Liquid Biopsy Market
出版日期: 2019年05月30日內容資訊: 英文 210 Pages
簡介

本報告提供全球液態切片市場調查,癌症的診斷,治療及監測相關資訊,目前檢驗和開發中的檢驗,競爭要素,市場趨勢,癌症的各類型的市場分析,及主要企業簡介等彙整。

第1章 摘要整理

第2章 液態切片技術

  • 簡介
  • 目前主要液態切片技術

第3章 循環腫瘤DNA (ctDNA) 液態切片

  • 簡介
  • 液態切片的ctDNA的優點及缺點
  • 目前ctDNA型液態切片檢驗
  • 開發中的ctDNA型液態切片檢驗

第4章 循環腫瘤細胞 (CTCs) 液態切片

  • 簡介
  • CTC型液態切片檢驗的開發中的課題
  • CTC型液態切片檢驗
  • 開發中的CTC型液態切片檢驗

第5章 細胞外小胞以及其他的液態切片

  • 簡介
  • 細胞外小胞/其他分析物為基礎的液態切片檢驗

第6章 多分析物液態切片檢驗

  • 簡介
  • 多分析物為基礎液態切片檢驗
  • 開發中的多分析物為基礎液態切片檢驗

第7章 研究目的專用的液態切片檢驗

  • 簡介
  • 研究目的專用的液態切片檢驗

第8章 液態切片產業分析

  • 簡介
  • 競爭的等級
  • 競爭要素
  • 重要的市場趨勢
  • 從液態切片市場撤退的企業

第9章 液態切片市場

  • 市場概要
  • 市場預測

第10章 市場:各分析物

  • 循環腫瘤DNA
  • 循環腫瘤細胞
  • 細胞外小胞以及其他分析物
  • 多分析物

第11章 市場:各用途

  • 治療指導、監測
  • 診斷/篩檢
  • 疾病的預後

第12章 市場:癌症的各類型

  • 乳癌
  • 大腸癌
  • 肺癌
  • 卵巢癌
  • 前列腺癌
  • 其他癌症
  • 全癌症檢驗

第13章 液態切片企業的簡介

目錄
Product Code: 19-038

Liquid biopsies are a set of minimally invasive diagnostic methods that analyze tumor-derived materials that can be found circulating in biological fluids, to provide information for the diagnosis, treatment, and monitoring of cancer.

This report, “The World Liquid Biopsy Market”, from Kalorama Information, contains up-to-date information and useful data points for business planning:

  • Research vs. Clinical Liquid Biopsy
  • The Market for Liquid Biopsy by Region
  • The Market for Liquid Biopsy Market by Type of Analyte
  • The Market for CTC-based Liquid Biopsy
  • The Market for ctDNA-based Liquid Biopsy
  • The Market for EV and Exosome-based Liquid Biopsy
  • The Market for Multi-Analyte-based Liquid Biopsy
  • The Market for Other Liquid Biopsy
  • Liquid Biopsy Market by Type of Cancer (Breast, Lung, Colorectal, Ovarian, Prostate, Pan-Cancer, Other Cancer)
  • Selected ctDNA-based Liquid Biopsy Tests in Development
  • Selected Market-Available CTC-based Liquid Biopsy Tests, 2019
  • Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2019

While tissue biopsies and imaging techniques remain the current standards of care in the diagnosis of solid tumors, they have risks and limitations and limitations, some of which can be overcome by the use of liquid biopsy in clinical oncology, as an alternative or complementary technique to the current standards of care.

Liquid biopsy testing has many potential applications in aspects of clinical oncology, including:

  • Early detection and diagnosis / screening
  • Alternative testing method when tissue biopsy is difficult/impossible, or when the primary site of metastatic disease is unknown
  • Therapy personalization and monitoring - by molecular characterization of a patient's disease, clinicians can select the optimal course of therapy and monitor efficacy over time, as well as quickly react to adjust therapy should treatment resistance arise
  • Disease monitoring - to observe disease progression, tumor evolution, residual disease, and early detection of recurrence
  • Prognosis of disease

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • INTRODUCTION
  • LIQUID BIOPSY TECHNOLOGIES
  • INDUSTRY STRUCTURE
  • LIQUID BIOPSY MARKET REVENUES AND FORECAST
    • Figure 1-1: Global Liquid Biopsy Market by Geographic Region, 2016 (%)
    • Table 1-1: Global Liquid Biopsy Market Forecast by Region ($ millions), 2018-2023
    • Figure 1-2: Global Liquid Biopsy Market Forecast by Region $ millions), 2018-2023

CHAPTER TWO: LIQUID BIOPSY TECHNOLOGIES

  • INTRODUCTION
    • Table 2-1: Comparison of Tissue and Liquid Biopsy
  • CURRENT MAJOR LIQUID BIOPSY TECHNOLOGIES
    • Table 2-2: Advantages and Limitations of Major Liquid Biopsy Technologies

CHAPTER THREE: CIRCULATING TUMOR DNA (CTDNA) LIQUID BIOPSY

  • INTRODUCTION
  • ADVANTAGES AND LIMITATIONS OF CTDNA IN LIQUID BIOPSY
  • CURRENT CTDNA-BASED LIQUID BIOPSY TESTS
    • Table 3-1: Selected Market-Available ctDNA-based Liquid Biopsy Tests, 2019
  • Biocartis
  • Biocept
  • Biodesix
  • CellMax Life
  • Circulogene
  • Diacarta
  • Epigenomics
  • Foundation Medicine
  • Guardant Health
  • Inivata
  • LungLife AI
  • Myriad Genetics
  • NeoGenomics
  • OncoDNA
  • Personal Genomic Diagnostics
  • QIAGEN
  • Resolution Biosciences
  • Roche Diagnostics
  • Sysmex-Inostics
  • CTDNA-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT
    • Table 3-2: Selected ctDNA-based Liquid Biopsy Tests in Development
  • Exact Sciences
  • Freenome
  • GRAIL
  • Personal Genome Diagnostics
  • Tempus

CHAPTER FOUR: CIRCULATING TUMOR CELLS (CTCS) LIQUID BIOPSY

  • INTRODUCTION
  • CHALLENGES IN THE DEVELOPMENT OF CTC-BASED LIQUID BIOPSY TESTS
  • CTC-BASED LIQUID BIOPSY TESTS
    • Table 4-1: Selected Market-Available CTC-based Liquid Biopsy Tests, 2019
  • Adaptive Biotechnologies
  • Biocept
  • CellMax Life
  • Epic Sciences
  • GILUPI
  • LungLife AI
  • Menarini-Silicon Biosystems
  • QIAGEN
  • CTC-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT
    • Table 4-2: Selected CTC-based Liquid Biopsy Tests in Development, 2019
  • ANGLE
  • Epic Sciences
  • Liquid Biotech USA

CHAPTER FIVE: EXTRACELLULAR VESICLES AND OTHER LIQUID BIOPSY

  • INTRODUCTION
  • LIQUID BIOPSY TESTS BASED ON EXTRACELLULAR VESICLES / OTHER ANALYTES
    • Table 5-1: Selected Market-Available Liquid Biopsy Tests based on Extracellular Vesicles / Other Analytes, 2019
  • Biodexis
  • Exosome Diagnostics
  • Hologic
  • MDxHealth
  • Vermillion
  • EXTRACELLULAR VESICLE/OTHER ANALYTE-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT
    • Table 5-2: Selected Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development, 2019
  • Circulogene
  • OncoCyte
  • QIAGEN
  • Resolution Biosciences
  • VolitionRx

CHAPTER SIX: MULTI-ANALYTE LIQUID BIOPSY TESTS

  • INTRODUCTION
  • LIQUID BIOPSY TESTS BASED ON MULTIPLE ANALYTES
    • Table 6-1: Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2019
  • Biocept
  • Biodesix
  • Foundation Medicine
  • LungLife AI
  • NeoGenomics
  • OncoDNA
  • MULTIPLE ANALYTE-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT
    • Table 6-2: Selected Multi Analyte-based Liquid Biopsy Tests in Development, 2019
  • Exact Sciences
  • Freenome
  • GRAIL
  • LungLife AI

CHAPTER SEVEN: LIQUID BIOPSY TESTS FOR RESEARCH USE ONLY

  • INTRODUCTION
  • LIQUID BIOPSY TESTS FOR RESEARCH USE ONLY
    • Table 7-1: Selected Liquid Biopsy Tests for Research Use Only, 2019
  • Agena Bioscience
  • ANGLE
  • DiaCarta
  • Exosome Diagnostics
  • Guardant Health
  • Natera
  • QIAGEN

CHAPTER EIGHT: LIQUID BIOPSY INDUSTRY ANALYSIS

  • INTRODUCTION
  • TIERS OF COMPETITION
    • Table 8-1: Selected Participants in the Liquid Biopsy Market, 2019
  • COMPETITIVE FACTORS
  • SIGNIFICANT MARKET TRENDS
    • Table 8-2: Significant Trends in the Liquid Biopsy Market, 2019
  • Personalized Medicine
  • Increasing Global Life Expectancy
  • New Liquid Biopsy Products
  • Increasing Accessibility of Genetic Testing
    • Figure 8-1: Laboratory Testing Sites - Tests Performed by Vendor vs. Testing Performed by Outside Labs (%)
  • Regulatory Hurdles
  • Third-Party Payor Coverage
  • Demonstrated Clinical Utility
  • Incidence Rates of Specific Cancers
  • COMPETITORS NO LONGER IN THE LIQUID BIOPSY MARKET
    • Table 8-3: Summary of Companies That Have Exited the Liquid Biopsy Market

CHAPTER NINE: LIQUID BIOPSY MARKET

  • MARKET OVERVIEW
    • Figure 9-1: Global Liquid Biopsy Diagnostics Market Estimate by Analyte, 2018 (%)
    • Figure 9-2: Global Liquid Biopsy Diagnostics Market Estimate by Region, 2018 (%)
    • Figure 9-3: Global Liquid Biopsy Market Estimate by Type of Use, (Research Use, Clinical Diagnostics Use) 2018 (%)
    • Figure 9-4: Global Liquid Biopsy Market by Test Performance Model (In-House Labs, Outside Clinical Labs, Both Options Available) (%)
  • MARKET FORECAST
    • Table 9-1: Global Liquid Biopsy Market Forecast by Region - North America, Europe, Asia Pacific, Rest of World, World ($ millions), 2018-2023
    • Figure 9-5: Global Liquid Biopsy Market Forecast by Region - North America, Europe, Asia Pacific, Rest of World ( $ millions), 2018-2023

CHAPTER TEN: MARKET BY ANALYTE

  • CIRCULATING TUMOR DNA
    • Market Overview
    • Revenue Forecast
      • Table 10-1: Global Liquid Biopsy Market for ctDNA ($ millions), 2018-2023
  • CIRCULATING TUMOR CELLS
    • Market Overview
    • Revenue Forecast
      • Table 10-2: Global Liquid Biopsy Market for CTCs ($ millions), 2018-2023
  • EXTRACELLULAR VESICLES AND OTHER ANALYTES
    • Market Overview
    • Revenue Forecast
      • Table 10-3: Global Liquid Biopsy Market for Extracellular Vesicles ($ millions), 2018-2023
  • MULTIPLE ANALYTES
    • Market Overview
    • Revenue Forecast
      • Table 10-4: Global Liquid Biopsy Market for Multiple Analytes ($ millions), 2018-2023

CHAPTER ELEVEN: MARKET BY APPLICATION

  • THERAPY GUIDANCE AND MONITORING
    • Market Overview
    • Revenue Forecast
      • Table 11-1: Liquid Therapy for Therapy Guidance ($ millions), 2018-2023
  • DIAGNOSIS/SCREENING
    • Market Overview
    • Revenue Forecast
      • Table 11-2: Global Liquid Biopsy Market for Diagnosis and Screening ($ millions), 2018-2023
  • DISEASE PROGNOSIS
    • Market Overview
    • Revenue Forecast
      • Table 11-3: Global Liquid Biopsy Market for Disease Prognosis ($ millions), 2018-2023

CHAPTER TWELVE: MARKET BY CANCER TYPE

  • BREAST CANCER
    • Market Overview
    • Revenue Forecast
      • Table 12-1: Global Liquid Biopsy Market for Breast Cancer ($ millions), 2018-2023
  • COLORECTAL CANCER
    • Market Overview
    • Revenue Forecast
      • Table 12-2: Global Liquid Biopsy Market for Colorectal Cancer ($ millions), 2018-2023
  • LUNG CANCER
    • Market Overview
    • Revenue Forecast
      • Table 12-3: Global Liquid Biopsy Market for Lung Cancer ($ millions), 2018-2023
  • OVARIAN CANCER
    • Market Overview
    • Revenue Forecast
      • Table 12-4: Global Liquid Biopsy Market for Ovarian Cancer ($ millions), 2018-2023
  • PROSTATE CANCER
    • Market Overview
    • Revenue Forecast
      • Table 12-5: Global Liquid Biopsy Market for Prostate Cancer ($ millions), 2018-2023
  • OTHER CANCERS
    • Market Overview
    • Revenue Forecast
      • Table 12-6: Global Liquid Biopsy Market for Other Cancers ($ millions), 2018-2023
  • PAN-CANCER TESTS
    • Market Overview
    • Revenue Forecast
      • Table 12-7: Global Liquid Biopsy Market for Pan-Cancer Testing ($ millions), 2018-2023

CHAPTER THIRTEEN: LIQUID BIOPSY COMPANY PROFILES

  • TOP TEN COMPANIES IN THE LIQUID BIOPSY MARKET
    • Table 13-1: Top Ten Companies in the Liquid Biopsy Market
  • ADAPTIVE BIOTECHNOLOGIES
  • AGENA BIOSCIENCE, INC.
  • ANGLE, PLC
  • BIOCARTIS GROUP NV
  • BIOCEPT, INC.
  • BIODESIX
  • CELLMAX LIFE
  • CIRCULOGENE
  • DIACARTA, INC.
  • EPIC SCIENCES
  • EPIGENOMICS AG
  • EXACT SCIENCES
  • EXOSOME DIAGNOSTICS, INC.
  • FOUNDATION MEDICINE, INC.
  • FREENOME, INC.
  • GENOMIC HEALTH, INC.
  • GILUPI GMBH
  • GRAIL
  • GUARDANT HEALTH, INC.
  • HOLOGIC
  • INIVATA
  • LIQUID BIOTECH USA
  • LUNGLIFE AI (FORMERLY CYNVENIO BIOSYSTEMS)
  • MDXHEALTH
  • MENARINI-SILICON BIOSYSTEMS, SPA
  • MYRIAD GENETICS, INC.
  • NATERA, INC.
  • NEOGENOMICS LABORATORIES, INC.
  • ONCOCYTE CORPORATION
  • ONCODNA S.A.
  • PERSONAL GENOME DIAGNOSTICS
  • QIAGEN N.V.
    • Cell-free DNA Technologies
    • CTC Technologies
    • Exosome and miRNA Technologies
  • RESOLUTION BIOSCIENCES
  • ROCHE DIAGNOSTICS
  • SYSMEX-INOSTICS, INC.
  • TEMPUS
  • VERMILLION, INC.
  • VOLITIONRX